Rosalind Advisors Inc. Raises Stake in InspireMD, Inc. $NSPR

Rosalind Advisors Inc. increased its holdings in InspireMD, Inc. (NYSE:NSPR) by 70.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 3,905,743 shares of the company’s stock after buying an additional 1,616,644 shares during the period. InspireMD accounts for about 3.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 13th biggest position. Rosalind Advisors Inc. owned approximately 0.09% of InspireMD worth $9,413,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Creative Planning purchased a new stake in shares of InspireMD in the 2nd quarter valued at $44,000. Uniting Wealth Partners LLC acquired a new position in InspireMD during the third quarter valued at $51,000. Vestia Personal Wealth Advisors lifted its position in InspireMD by 135.7% during the third quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock valued at $102,000 after purchasing an additional 24,425 shares during the period. Raymond James Financial Inc. boosted its holdings in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock valued at $101,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Courier Capital LLC boosted its holdings in InspireMD by 83.3% in the third quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock valued at $133,000 after purchasing an additional 25,000 shares during the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $1.65 on Friday. The company has a market capitalization of $69.91 million, a PE ratio of -2.20 and a beta of 0.87. The company’s fifty day moving average price is $1.70 and its 200 day moving average price is $2.01. InspireMD, Inc. has a 1 year low of $1.51 and a 1 year high of $2.99.

Insider Buying and Selling at InspireMD

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total value of $28,500.66. Following the completion of the transaction, the insider owned 1,174,664 shares in the company, valued at approximately $1,902,955.68. This represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 61,194 shares of company stock valued at $99,188 in the last three months. Corporate insiders own 29.72% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on NSPR shares. Loop Capital set a $5.00 price objective on InspireMD in a research note on Tuesday, February 24th. Maxim Group started coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Finally, Lake Street Capital reaffirmed a “buy” rating on shares of InspireMD in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $5.00.

InspireMD Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.